| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,316 | 0,330 | 11.04. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Edison Group: Edison Issues Report on MindMaze Therapeutics (MMTX) | 311 | Newsfile | London, United Kingdom--(Newsfile Corp. - April 7, 2026) - Edison issues report on MindMaze Therapeutics (SIX: MMTX).MindMaze Therapeutics is a commercial-stage health technology company pioneering... ► Artikel lesen | |
| 31.03. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics and Vibra Healthcare Announce Breakthrough RWE Results in High-Dose, High-Intensity Neurorehabilitation | 595 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Study results
MindMaze Therapeutics and Vibra Healthcare Announce Breakthrough RWE Results in High-Dose, High-Intensity Neurorehabilitation... ► Artikel lesen | |
| 19.03. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank | 499 | EQS Group (EN) | MindMaze Therapeutics Holding SA
/ Key word(s): Miscellaneous
MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank
19.03.2026 / 07:00 CET/CEST
MindMaze... ► Artikel lesen | |
| 12.03. | MindMaze Therapeutics Holding Names Zach Henderson CEO | 23 | RTTNews | ||
| 12.03. | MindMaze ernennt Zach Henderson zum neuen CEO | 14 | Investing.com Deutsch | ||
| 12.03. | MindMaze names Zach Henderson as chief executive officer | 6 | Investing.com | ||
| 12.03. | MindMaze Therapeutics Holding SA: MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale | 418 | ACCESS Newswire | Former Rune Labs and Glooko executive to lead MindMaze's next phase of growth, focusing on U.S. market expansion and the delivery of scalable, AI-driven neurorestorative care. GENEVA, SWITZERLAND /... ► Artikel lesen | |
| 12.03. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale | 1.428 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Personnel
MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale
12-March-2026 / 07:00... ► Artikel lesen | |
| MINDMAZE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.03. | Adhoc: MindMaze Therapeutics Holding SA: MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation | 1.174 | EQS Group (EN) | MindMaze Therapeutics Holding SA / Key word(s): Miscellaneous
MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation
03-March-2026 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 23.12.25 | MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics | 563 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Miscellaneous
MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
23.12.2025... ► Artikel lesen | |
| 18.12.25 | Edison Group: Edison Issues Report on MindMaze Therapeutics (MMTX) | 628 | Newsfile | London, United Kingdom--(Newsfile Corp. - December 18, 2025) - Edison issues report on MindMaze Therapeutics (SIX: MMTX).MindMaze Therapeutics is a commercial-stage health technology company pioneering... ► Artikel lesen | |
| 15.12.25 | MindMaze Therapeutics - The next frontier of precision neurotherapeutics | 936 | Edison Investment Research | MindMaze Therapeutics is a commercial-stage health technology company pioneering AI-driven digital neurotherapeutic solutions for treatment and recovery after neurological events such as stroke and... ► Artikel lesen | |
| 15.12.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics | 1.354 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
15-Dec-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 25.11.25 | Relief Therapeutics Publishes Joint Deck Ahead Of NeuroX Merger; Stock Up | 5 | RTTNews | ||
| 25.11.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination | 1.562 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination... ► Artikel lesen | |
| 14.11.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Shareholders Approve Business Combination with NeuroX | 3.236 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
14-Nov-2025 / 18:20 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 29.10.25 | Relief Therapeutics Shares Surge On Positive Results Of RLF-OD032 Bioequivalent Study | 26 | RTTNews | ||
| 29.10.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 | 1.348 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
29-Oct-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 24.10.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Convenes Extraordinary General Meeting | 1.861 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Convenes Extraordinary General Meeting
24-Oct-2025 / 06:59 CET/CEST
Release of an ad hoc announcement pursuant... ► Artikel lesen | |
| 08.10.25 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination | 1.975 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination
08-Oct-2025... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech, Newron und Emyria: Biotech-Unternehmen rücken in den Fokus einer neuen Substanzdebatte | ||
| EVOTEC | 4,530 | +0,09 % | EQS-News: Evotec SE: Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden
07.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| BB BIOTECH | 48,350 | 0,00 % | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| MEDIGENE | 0,025 | -18,83 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 43,330 | -0,30 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| PAION | 0,051 | -19,84 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,668 | -1,11 % | Valneva mit Rekordsignal: Was große Adressen zum Wochenstart bereits wissen - Was erfahrene Anleger jetzt analysieren | ||
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| EPIGENOMICS | 0,920 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| STRYKER | 289,50 | +0,10 % | Stryker confident of 2026 outlook despite Q1 impact from cyberattack | ||
| BIOGEN | 147,04 | -0,28 % | Biogen to acquire Apellis in $5.6bn deal | ||
| BIOFRONTERA | 2,610 | +2,35 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| HEIDELBERG PHARMA | 2,810 | +3,31 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen |